Xequel Bio, Inc.

Xequel Bio, Inc., doing business as FSR, is a for-profit corporate entity that provides biomedical research and development services to U.S. federal agencies, primarily the Department of Health and Human Services and the Department of Defense. Through federal contracts and grants, the company pursues innovative solutions for public health priorities such as infectious disease, medical countermeasures, regenerative medicine, and battlefield medicine.

Xequel Bio has been awarded several federal contracts to advance the development of therapeutic candidates, diagnostics, and medical devices. This includes a $6.5 million contract from the National Institutes of Health to develop a topical therapeutic for radiation injury, a $750,000 contract from the HHS Office of the Assistant Secretary for Preparedness and Response to evaluate drug candidates for lung injury treatment, and contracts from the Defense Health Agency and Army Medical Command supporting wound healing and regenerative medicine research. The contracts were awarded on a competitive basis with no set-aside designations.

Through federal grants, Xequel Bio conducts biomedical research aligned with priorities in eye health, lung disease, kidney disease, burn care, radiation exposure, and COVID-19. Major granting agencies include the National Institutes of Health, the Defense Health Agency, and the Army Medical Command. Recent awards provide over $2 million to develop corneal and retinal regenerative therapies, $1.7 million to study COVID-19 acute respiratory distress syndrome, and $5 million to improve outcomes for marginal organ transplants. The company has also received substantial funding as a prime grantee under the Military Medical Research and Development program supporting innovative solutions for battlefield trauma.